Skip to main content

Table 1 A summary of the study data, subject demographics and covariates included in the analysis.

From: Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects

Characteristic Single dose study Drug interaction study Food effect study Multiple dose study Combined
No. of subjects 28 19 20 24 91
No. of concentration-time profiles 28 28 38 24 118
No. of observations      
   AS 206 207 324 179 916
   DHA 316 314 449 273 1352
AS dose (mg/kg) 2, 3, 4 or 5 4 4 2, 3, 4 or 5 2, 3, 4 or 5
Sampling schedule Predose, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.5, 3, 4, 5, 8 and 12 h postdose Predose, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.5, 3, 4, 5, 8 and 12 h postdose Predose, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.5, 3, 4, 5, 8 and 12 h postdose Immediately prior to each dose and 0.33, 0.67, 1, 1.33, 1.67, 2, 2.5, 3, 4, 5, 8 and 12 h after the third dose NA
Age (years) 24 (19-40) 23 (20-32) 21.5 (19-27) 23 (19-29) 23 (19-40)
Weight (kg) 62.5 (50.4-70) 60.9 (50.1-67.1) 59.9 (50.8-68.5) 62.2 (51.2-68.8) 61.5 (50.1-70)
Sex (number)      
   Female 9 10 10 9 38
   Male 19 9 10 15 53
Type of dosing Single Single Single Multiple (once daily for 3 days) NA
Food intake (number of profiles)      
   Fasted 28 28 19 24 99
   Fed 0 0 19 0 19
  1. AS, artesunate; DHA, dihydroartemisinin.
  2. Continuous variables are given as median (range).